EUNew treatments and approvals
Levacetylleucine approved in the EU for nervous system symptoms of Niemann-Pick type C
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
On January 19, 2026, the European Commission approved levacetylleucine for Niemann-Pick type C disease. The drug is for nervous system symptoms such as problems with balance, movement and speech. It is used in patients older than 6 years who weigh at least 20 kg. It can be given together with miglustat or on its own. In the main study of 60 people, balance and movement scores improved.
What does it mean for patients and families?
A second drug option for these symptoms has become available in Europe. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Niemann-Pick disease type C (NPC)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.